Current antifungal treatment of fusariosis

Abdullah M. S. Al-Hatmi , Alexandro Bonifaz , Stephane Ranque (1) , G. Sybren De Hoog , Paul E. Verweij , Jacques F. Meis

1 VITROME - Vecteurs - Infections tropicales et méditerranéennes

Fungi of the genus Fusarium are well known as major plant pathogens and soil inhabitants, but also cause a broad spectrum of human infections. Fusariosis is the second most common mould infection after aspergillosis, and keratitis is the most encountered implantation infection in immunocompetent individuals. Natamycin is active against Fusarium species both in vitro and in vivo, and is used along with voriconazole as the mainstay of treatment for Fusarium keratitis. Onychomycosis is treated with terbinafine, voriconazole and sometimes itraconazole. Cure is possible despite high in vitro minimum inhibitory concentrations (MICs). Recently, disseminated infections have increased dramatically, mainly affecting severely immunocompromised patients. The remarkable intrinsic resistance of Fusarium species to most antifungal agents results in high mortality rates in this patient population. Recovery of neutropenia is essential for patient survival and treatment should include voriconazole or amphotericin B as first-line and posaconazole as salvage therapy. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Domaines: Maladies infectieuses

Abdullah M. S. Al-Hatmi, Alexandro Bonifaz, Stephane Ranque, G. Sybren De Hoog, Paul E. Verweij, et al.. Current antifungal treatment of fusariosis. International Journal of Antimicrobial Agents, 2018, 51 (3), pp.326-332. ⟨10.1016/j.ijantimicag.2017.06.017⟩. ⟨hal-01789209⟩